Cost-effectiveness of pretreatment HIV drug resistance testing in people living with HIV in Iran
Based on our findings, pretreatment HIVDR testing is not currently cost-effective in Iran as it imposes high costs on healthcare systems with few benefits for People living with HIV (PLHIV). However, if resources are available, drug resistance testing can be a valuable tool in generating HIV molecular data and molecular surveillance of HIV.
Authors
- Fatemeh Mehrabi (ORCID: https://orcid.org/0000-0003-4059-474X)
- Firooz Esmaeilzadeh (ORCID: https://orcid.org/0000-0002-7068-5688)
- Ebrahim Ranjbar
- Mohsen Barouni (ORCID: https://orcid.org/0000-0001-6955-0818)
- Abedin Iranpour (ORCID: https://orcid.org/0000-0002-7746-5709)
- Hamid Pour Sharifi (ORCID: https://orcid.org/0000-0002-9008-7618)
- Hossein Mirzaei (ORCID: https://orcid.org/0000-0002-8033-9762)
Institutions
- University of Maragheh (IR)
- University of California, San Francisco (US)
- Kerman University of Medical Sciences (IR)
- Global Brain Health Institute (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1371/journal.pone.0309528
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Kerman University of Medical Sciences
- Student Research Committee, Tabriz University of Medical Sciences